Frovocimab
Frovocimab Basic information
- Product Name:
- Frovocimab
- Synonyms:
-
- Frovocimab
- Research Grade Frovocimab(DHJ24003)
- Research Grade Frovocimab
- Frovocimab (anti-PCSK9)
- CAS:
- 1643672-70-1
- MW:
- 0
- Mol File:
- Mol File
Frovocimab Usage And Synthesis
Uses
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9[1].
in vivo
Frovocimab (LY 3015014; 10 mg/kg; i.v; once) causes significant PCSK9 accumulation, its duration of LDL lowering is reduced, and its clearance (CL) from serum is accelerated in mice expressing a noncleavable variant of human PCSK9[1].
Frovocimab (LY 3015014; 5 mg/kg; i.v; once) decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact PCSK9 in serum[1].
| Animal Model: | Male C57BL/6NTac mice injected with vector containing the NC R215A/R218A variant[1] |
| Dosage: | 10 mg/kg |
| Administration: | i.v; once |
| Result: | Caused significant PCSK9 accumulation. |
| Animal Model: | Cynomolgus monkeys[1] |
| Dosage: | 5 mg/kg |
| Administration: | i.v; once |
| Result: | Decreased LDL cholesterol in monkeys. |
References
[1] Krista M Schroeder, et al. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. J Lipid Res. 2015 Nov;56(11):2124-32. DOI:10.1194/jlr.M061903
FrovocimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com